Equity Components [Axis]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Statistical Measurement [Axis]
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
ATM Sales Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
License Strategic Alliance and Research Agreements [Member]
Statement of Income Location Balance [Axis]
Research and Development Expenses [Member]
Legal Entity [Axis]
BioNumerik Pharmaceuticals [Member]
Assignment Agreement [Member]
AFC License Agreement [Member]
AF Chemicals [Member]
Allarity Therapeuties [Member]
Asset Purchase Agreement [Member]
Fortrea Inc [Member]
Fortrea Agreement [Member]
Patheon API Services [Member]
Patheon Agreement [Member]
Piramal Pharma Solutions [Member]
Piramal Pharma Agreement [Member]
Vivo Pharm [Member]
Vivo Pharm Agreement [Member]
Fox Chase Cancer Center [Member]
Research Agreement [Member]
Berkshire Sterile Manufacturing [Member]
Berkshire Agreement [Member]
Shilpa Medicare Limited [Member]
Shilpa Agreement [Member]
Curia Global, Inc. [Member]
Curia Agreement [Member]
Harvest Integrated Research Organization [Member]
Harvest Integrated Research Organization Agreement [Member]
Actuate Therapeutics [Member]
Collaboration Agreement [Member]
Sale of Stock [Axis]
Reverse Stock Split and IPO [Member]
Class of Stock [Axis]
Series A Preferred Stock [Member]
IPO [Member]
Title and Position [Axis]
Consultants [Member]
Award Type [Axis]
Restricted Stock [Member]
Plan Name [Axis]
2018 Equity Incentive Plan [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Warrant [Member]
2018 Equity Incentive Plan [Member]
General and Administrative Expenses [Member]
Asset Class [Axis]
Cash and Cash Equivalents [Member]
Financial Instrument [Axis]
US Government Debt Securities [Member]
Equity Securities [Member]
Marketable Securities [Member]
Corporate Debt Securities [Member]
Debt Securities [Member]
Investment Type [Axis]
US Government Agencies Short-Term Debt Securities [Member]
Fair Value Hierarchy and NAV [Axis]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Inputs, Level 3 [Member]
Money Market Funds [Member]
Mutual Funds Fixed Income [Member]
Mutual Funds Alternative Investments [Member]
Corporate Bond Securities [Member]
Antidilutive Securities [Axis]
Unvested Restricted Shares [Member]
Share-Based Payment Arrangement, Option [Member]
Income Tax Jurisdiction [Axis]
Domestic Tax Jurisdiction [Member]
Research and Development Studies [Member]
Research and Development Materials [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Entity Listing, Par Value Per Share
Auditor Firm ID
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Statement of Financial Position [Abstract]
CURRENT ASSETS
Cash and cash equivalents
Marketable securities
Prepaid expenses & other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Deferred offering costs
Other assets
TOTAL ASSETS
CURRENT LIABILITIES
Accounts payable and accrued expenses
Operating lease liabilities, current
Total current liabilities
Operating lease liabilities, net of current portion
TOTAL LIABILITIES
COMMITMENTS AND CONTINGENCIES (NOTE 4)
STOCKHOLDERS’ EQUITY
Preferred Stock (1,000,000 authorized at December 31, 2025 and December 31, 2024; $.0001 par value) (Zero shares issued and outstanding at December 31, 2025 and December 31, 2024)
Common Stock (25,000,000 authorized at December 31, 2025 and December 31, 2024; $.0001 par value) (11,254,697 shares issued and outstanding at December 31, 2025; 10,784,725 shares issued and outstanding at December 31, 2024)
Additional paid-in capital
Accumulated other comprehensive income
Accumulated deficit
Total stockholders’ equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, shares authorized
Common stock, par value
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
General and administrative
Research and development
Total operating expenses
Loss from operations
Interest income
Other income, net
NET LOSS
Net loss per share of common shares, basic
Net loss per share of common shares, diluted
Weighted-average number of common shares outstanding, basic
Weighted-average number of common shares outstanding, diluted
NET LOSS
Other comprehensive (loss) gain
Unrealized (loss) gain on available-for-sale securities
Unrealized (loss) gain on foreign currency translation
Other comprehensive (loss) gain
Comprehensive loss
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Issuance of restricted common stock awards
Issuance of restricted common stock awards, shares
Proceeds from warrant exercises
Proceeds from warrant exercises, shares
Stock-based compensation
Net loss
Other comprehensive loss
Net proceeds from issuance of common stock, net of issuance costs of $61,318
Net proceeds from issuance of common stock, net of issuance costs, shares
Issuance of restricted common stock for services
Issuance of restricted common stock for services, shares
Proceeds from the exercise of stock options
Proceeds from exercise of stock options, shares
Balance
Balance, shares
Statement of Stockholders' Equity [Abstract]
Proceeds from issuance of cost
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization
Accretion of discounts on available for sale debt securities, net
Non-cash lease adjustments
Issuance of restricted common stock for services
Stock-based compensation
Foreign currency remeasurement (gain) loss
Realized gain on redemptions of available for sale debt securities
Realized loss on equity securities
Unrealized gain on equity securities
Changes in assets and liabilities:
Operating lease liabilities
Prepaid expenses & other current assets
Accounts payable and accrued expenses
Other assets
Net cash flows used in operating activities
INVESTING ACTIVITIES
Purchase of property and equipment
Purchase of marketable securities
Redemptions of marketable securities
Net cash flows provided by investing activities
FINANCING ACTIVITIES
Proceeds from option exercises
Proceeds from warrant exercises
Proceeds from the issuance of common stock under the ATM Sales Agreement
Payments of offering cost related to the ATM Sales Agreement
Net cash flows provided by financing activities
Effect of foreign exchange rates on cash
CHANGE IN CASH AND CASH EQUIVALENTS FOR THE YEAR
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR
CASH AND CASH EQUIVALENTS, END OF YEAR
Non-cash investing and financing activities:
Operating lease right-of-use asset acquired through operating lease liability
Removal of operating lease right-of-use assets and related operating lease liabilities upon early termination of leases
Deferred offering costs included in accounts payable and accrued expenses
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b5-1 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b5-1 Arrangement Terminated
Non-Rule 10b5-1 Arrangement Terminated
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Principal Activities, and Basis of Presentation
Liquidity and Going Concern
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Leases
Leases
Equity [Abstract]
Shareholders’ Equity
Cash and Cash Equivalents [Abstract]
Marketable Securities
Fair Value Disclosures [Abstract]
Fair Value Measurements
Earnings Per Share [Abstract]
Loss Per Share of Common Shares
Income Tax Disclosure [Abstract]
Income Taxes
Segment Reporting [Abstract]
Segment Reporting
Use of Estimates and Assumptions
Foreign Currency
Risks and Uncertainties
Research and Development
Cash and Cash Equivalents
Prepaid Expenses and Other Current Assets
Leases
Marketable Securities
Deferred Offering Costs
Income Taxes
Stock-based Compensation
Recently Adopted Accounting Pronouncement
New Accounting Pronouncements Not Yet Adopted
Schedule of Research and Development
Schedule of Accounts Payable and Accrued Liabilities
Schedule of Balance Sheet Information Related to Leases
Schedule of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases
Schedule of Reconciliation of Right-of-Use Assets and lease Liabilities
Schedule of Other Supplemental Information Related to Operating Leases
Schedule of Lease Expense
Schedule of Stock Option Activity
Schedule of Stock-based Compensation
Schedule of Weighted Average Assumptions
Schedule of Marketable of Securities
Schedule of Contractual Maturities Investments of Marketable Securities
Schedule of Assets are Measured at Fair Value on Recurring Basis
Schedule of Anti-dilutive Securities Outstanding Diluted Loss Per Share
Schedule of Effective Income Tax Rate
Schedule of Deferred Tax Assets and Liabilities
Schedule of Segment Reporting Information
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss
Working capital
Maximum aggregate offering price
Number of shares sold
Proceeds from issuance of common stock
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Cash FDIC insured amount
Cash and cash equivalents
Prepaid expense and other current assets
Upfront payments for contractor fees, academic research studies and services, and subscriptions
Prepaid annual insurance fees
Interest receivable
Allowance for credit losses
Deferred offering costs
Deferred offering cost remaining under ATM
Research and Development, Contract to Perform for Others [Table]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Amount Expensed for License, Strategic Alliance, and Research Agreements
Amount accrued and payable under License, Strategic Alliance, and Research Agreements
Prepaid expenses and other current assets under License, Strategic Alliance, and Research Agreements
CommitmentsAndContingenciesDisclosureTable [Table]
Upfront payments
Commitments description
Research and development expenses
Future payments
Reduction in rsearch and development expenses
Actuate stock of restricted shares
Nominal value acquired cost
Number of shares hold
Fair value
Schedule Of Balance Sheet Information Related To Leases
Operating lease, right-of-use asset, net
Current portion of operating lease liabilities
Total operating lease liabilities
Schedule Of Future Estimated Minimum Lease Payments Under Non-cancelable Operating Leases
Total minimum lease payments to be paid in 2026
Less amount representing interest
Present value of future minimum lease payments
Less current portion of operating lease liabilities
Operating Right-of-Use Assets, Beginning Balance
Operating Lease Liabilities, Beginning Balance
Operating Right-of-Use Assets, Early termination of Legacy West Leases
Operating Right-of-Use Assets, Early termination of Legacy West Leases
Operating Right-of-Use Assets, Operating right-of-use asset acquired through operating lease liability
Operating Lease Liabilities, Operating right-of-use asset acquired through operating lease liability
Operating Right-of-Use Assets, Amortizations
Operating Lease Liabilities, Amortizations
Operating Right-of-Use Assets, Ending Balance
Operating Lease Liabilities, Ending Balance
Weighted average remaining term of operating leases (in years)
Weighted average discount rate of operating leases
Operating lease cost
Short-term lease cost
Lease expense
New lease payments
Operating lease term
Remaining lease term
Cash used in operating activities associated with leases
Number of options outstanding, beginning balance
Weighted average exercise price per share, outstanding beginning
Number of options exercisable, beginning valance
Number of options exercisable, weighted-average exercise price, beginning balance
Number of shares, granted
Weighted average exercise price per share, granted
Number of shares, cancelled or expired
Weighted average exercise price per share, cancelled or expired
Number of shares, exercised
Weighted average exercise price per share, exercised
Number of shares, outstanding beinning
Weighted average exercise price per share, outstanding ending
Number of options exercisable, ending balance
Number of options exercisable, weighted-average exercise price, ending balance
EquityTable [Table]
Stock-based compensation
Term (in years)
Risk Free Rate
Volatility
Dividend Yield
Grant Date Fair Value
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted
Preferred stock shares authorized
Restricted stock vested, shares
Fair value of restricted shares
Allocated share based compensation
Number of shares to be issued for placement shares offering or sales agent
Percentage of sales on placement shares
Number of shares issued
Sale of equity
Commissions and transaction costs
Options exercised
Shares issued price per share
Cash receipts
Exercise of warrants
Number of shares issued for cashless exercise of warrants
Warrants outstanding
Number of reserved shares
Weighted average remaining contractual term of exercisable options
Number of remain available shares
Exercise price of options
Weighted average price percentage
Stock compensation expense
Incremental compensation cost
Unrecognized share based compensartion
Weighted average period
Weighted average remaining contractual term of outstanding options
Intrinsic value of options outstanding
Intrinsic value of options exercisable
Unrecognized compensation expense
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Aggregate fair value
Aggregate Fair Value
Due within one year
Impairment Effects on Earnings Per Share [Table]
Impairment Effects on Earnings Per Share [Line Items]
Equity securities
Debt securities
Fair Value, off-Balance-Sheet Risk [Table]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value recurring basis
Total
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
U.S. federal statutory tax rate
US federal statutory tax rate, percent
Research and development credits
Research credits, percent
Nontaxable or nondeductible items
Other, percent
Changes in valuation allowance
Valuation allowance, percent
Effective Income Tax Rate
Effective income tax rate, percent
Permanent differences, percent
Deferred tax assets
Research and development credits
Stock-based compensation
Net operating loss carryforwards
Research and development amortization
Deferred tax asset
Less: valuation allowance
Net deferred tax asset
Deferred tax liabilities
Unrealized gains on securities
Operating lease right-of-use assets
Fixed assets
Net deferred tax assets
Net loss before income taxes
Net loss before income taxes
Net operating loss carryforwards for federal income tax
Net operating loss carryforwards, description
Net operating loss carryforwards, state
Net operating loss carryforwards, foreign
Research and development tax credit carryforwards
Schedule of Segment Reporting Information, by Segment [Table]
Cash
Cash equivalents
Research and development costs
Number of operating segment
Amount expensed for license strategic alliance and research agreements.
License Strategic Alliance and Research Agreements [Member]
Upfront payments.
BioNumerik Pharmaceuticals [Member]
Assignment Agreement [Member]
AFC License Agreement [Member]
AF Chemicals [Member]
Allarity Therapeuties [Member]
Asset purchase agreement [Member]
Future payments.
Fortrea Inc [Member]
Fortrea Agreement [Member]
Patheon API Services [Member]
Patheon Agreement [Member]
Reduction in rsearch and development expenses.
Piramal Pharma Solutions [Member]
Piramal Pharma Agreement [Member]
Vivo Pharm [Member]
Vivo Pharm Agreement [Member]
Fox Chase Cancer Center [Member]
Research Agreement [Member]
Berkshire Sterile Manufacturing [Member]
Berkshire Agreement [Member]
Shilpa Medicare Limited [Member]
Shilpa Agreement [Member]
Curia Global, Inc. [Member]
Curia Agreement [Member]
Harvest Integrated Research Organization [Member]
Harvest Integrated Research Organization Agreement [Member]
Actuate Therapeutics [Member]
Collaboration Agreement [Member]
Number of hold shares.
Reverse Stock Split and IPO [Member]
Nominal value of restricted shares of actuate stock.
Schedule of Balance Sheet Information Related to Leases [Table Text Block]
Stock issued during period value common stock
Stock issued during period shares common stock
Schedule of Reconciliation of Right-of-use Assets and Lease Liabilities [Table Text Block]
Operating right-of-use assets, early termination.
Operating lease right of use asset acquired.
Operating lease liability amortization expense
Operating lease liability acquired
Operating lease liability early termination.
Removal of operating lease right of use assets and related operating lease liabilities upon early termination of leases.
Deferred offering costs included in accounts payable and accrued expenses.
Schedule Of Other Supplemental Information Related To Operating Leases [Table Text Block]
Working capital
ATM Sales Agreement [Member]
Consultants [Member]
Prepaid Expenses And Other Current Assets [Policy Text Block]
Upfront payments for contractor fees, academic research studies and services, and subscriptions.
2018 Equity Incentive Plan [Member]
Number of shares to be issued for placement shares offering or sales agent.
Percentage of sales on placement shares.
Stock issued during period value at market sales agreement maximum aggregate amount of proceeds.
2018 Equity Incentive Plan [Member]
Weighted average price percentage
New Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]
Share based compensation arrangement by share based payment award options exercised in period.
Marketable Securities [Member]
Research and development amortization.
Deferred tax liabilities operating lease right of use assets.
Statement of Income Location Balance [Axis]
General and Administrative Expenses [Member]
Research and Development Expenses [Member]
Research and Development Studies [Member]
Research and Development Materials [Member]
Mutual Funds Fixed Income [Member]
Mutual Funds Alternative Investments [Member]
Unvested Restricted Shares [Member]
2018 Equity Incentive Plan [Member] [Default Label]
Assets, Current
Assets
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Shares, Outstanding
Investment Income, Net, Amortization of Discount and Premium
Issuance of Stock and Warrants for Services or Claims
Employee Benefit and Share-Based Payment Arrangement, Noncash
Gain (Loss), Foreign Currency Transaction, before Tax
Debt Securities, Available-for-Sale, Realized Gain (Loss)
Unrealized Gain (Loss) on Investments
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Other Operating Assets
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Marketable Securities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Lessee, Operating Leases [Text Block]
Lessee, Leases [Policy Text Block]
Marketable Securities, Policy [Policy Text Block]
Income Tax, Policy [Policy Text Block]
WorkingCapital
Deferred Offering Costs [Default Label]
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
OperatingLeaseAssetsEarlyTermination
OperatingLeaseLiabilityEarlyTermination
Operating Lease, Right-of-Use Asset, Periodic Reduction
OperatingLeaseLiabilityAmortizationExpense
Lease, Cost
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Income Tax Expense (Benefit)
Deferred Tax Asset, In-Process Research and Development
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Liabilities, Unrealized Gains on Trading Securities
DeferredTaxLiabilitiesOperatingLeaseRightofuseAssets
Deferred Tax Liabilities, Property, Plant and Equipment
Deferred Tax Assets, Net
Income (Loss) from Continuing Operations before Income Taxes, Foreign